221 related articles for article (PubMed ID: 24930088)
1. PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
Zhu G; Chen G; Shi L; Feng J; Wang Y; Ye C; Feng W; Niu J; Huang Z
Mol Neurobiol; 2015 Feb; 51(1):32-42. PubMed ID: 24930088
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
[TBL] [Abstract][Full Text] [Related]
3. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
5. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
7. Protection against dopaminergic neurodegeneration in Parkinson's disease-model animals by a modulator of the oxidized form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.
Inden M; Kitamura Y; Takahashi K; Takata K; Ito N; Niwa R; Funayama R; Nishimura K; Taniguchi T; Honda T; Taira T; Ariga H
J Pharmacol Sci; 2011; 117(3):189-203. PubMed ID: 22041943
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
[TBL] [Abstract][Full Text] [Related]
9. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
11. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
Jalewa J; Sharma MK; Gengler S; Hölscher C
Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
13. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
[TBL] [Abstract][Full Text] [Related]
14. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Carbone M; Duty S; Rattray M
BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinson׳s disease.
Morroni F; Sita G; Tarozzi A; Cantelli-Forti G; Hrelia P
Brain Res; 2014 Nov; 1589():93-104. PubMed ID: 25257035
[TBL] [Abstract][Full Text] [Related]
16. Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
Yang PH; Zhu JX; Huang YD; Zhang XY; Lei P; Bush AI; Xiang Q; Su ZJ; Zhang QH
Neurodegener Dis; 2016; 16(5-6):357-69. PubMed ID: 27228974
[TBL] [Abstract][Full Text] [Related]
17. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
18. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
19. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
20. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
